GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmuPharma PLC (LSE:IMM) » Definitions » Common Stock

ImmuPharma (LSE:IMM) Common Stock : £28.98 Mil (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is ImmuPharma Common Stock?

ImmuPharma's quarterly common stock increased from Jun. 2022 (£2.85 Mil) to Dec. 2022 (£28.98 Mil) but then stayed the same from Dec. 2022 (£28.98 Mil) to Jun. 2023 (£28.98 Mil).

ImmuPharma's annual common stock increased from Dec. 2020 (£25.02 Mil) to Dec. 2021 (£28.50 Mil) and increased from Dec. 2021 (£28.50 Mil) to Dec. 2022 (£28.98 Mil).


ImmuPharma Common Stock Historical Data

The historical data trend for ImmuPharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmuPharma Common Stock Chart

ImmuPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.95 16.74 25.02 28.50 28.98

ImmuPharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.02 28.50 2.85 28.98 28.98

ImmuPharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


ImmuPharma (LSE:IMM) Business Description

Traded in Other Exchanges
Address
One Bartholomew Close, London, GBR, EC1A 7BL
ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus and a life-threatening autoimmune disease.

ImmuPharma (LSE:IMM) Headlines

No Headlines